Function of erythropoietin in the preventing and treating of retinal injury

A technology for erythropoietin and retinal damage, applied in the field of biomedicine, can solve the problems of inability to reach the eye, inability to protect the retina, side effects, etc.

Inactive Publication Date: 2007-10-31
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the application of EPO in the prior art is only limited to the treatment of spinal cord injury or craniocerebral injury, etc., and is only limited to systemic administration (such as intramuscular injection and blood administration). This mode of administration cannot make a sufficient amount of EPO The active ingredients reach the eye and cannot really protect the retina effectively
And this systemic administration will produce more serious side effects due to increased erythropoiesis and angiogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Function of erythropoietin in the preventing and treating of retinal injury
  • Function of erythropoietin in the preventing and treating of retinal injury
  • Function of erythropoietin in the preventing and treating of retinal injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0146] Example 1 Blood glucose and body weight changes in experimental rat diabetes model

[0147] After grouping according to the method described in I and preparing rat diabetes models, the following indicators were mainly observed in this embodiment: (1) changes in blood sugar and (2) changes in body weight after the rats were injected with STZ.

[0148] As a golden indicator for observing diabetes, changes in blood sugar can more accurately reflect the condition of diabetes in rats and the stability of the model. In the present invention, after a single intraperitoneal injection of STZ, the blood sugar rises sharply and briefly, and falls back to the normal level within 24 hours. Beginning the next day, blood glucose increased again and remained between 400-700 mg / dL for the rest of the time, indicating a stable diabetes model (see Figure 1A). At the same time, it can be seen that the blood sugar levels of rats in the diabetes group and the rats in the treatment group are b...

Embodiment 2

[0150] Example 2 Early blood-retinal barrier dysfunction in diabetic rats and the protective effect of intravitreous injection of EPO

[0151] The inventors used the Evans Blue method to quantitatively detect the permeability of the blood-retinal barrier. This assay is sensitive to disruption of the blood-retinal barrier in early diabetic rats. Evans Blue is mainly bound to albumin in the blood, so it cannot leak out of blood vessels under normal conditions. The diabetes model established by the inventors using STZ belongs to type 1 diabetes, which is prone to diabetic ketoacidosis. Take into account that blood pH may affect the binding of Evans Blue to albumin. At the same time, the vascular permeability of free EvansBlue increases under acidic conditions. In order to exclude the influence of acidic conditions on the permeability of Evans Blue. The present inventors used a small amount of insulin (4IU / week) subcutaneous injection to prevent the occurrence of diabetic keto...

Embodiment 3

[0155] Example 3 The protective effect of EPO on the blood-retinal barrier is dose-dependent

[0156] Diabetic rats received intravitreal injection of different doses of EPO (0.05-200ng / eye) at the time of onset, and injected equal volumes of normal saline into the vitreous cavity of normal control rats and diabetic control rats. After two weeks, the permeability of retinal Evans Blue in each group was measured.

[0157] The results showed that the protective effect of EPO on the blood-retinal barrier had an obvious dose-dependent relationship. As shown in Figure 4, low doses of EPO had no effect. When the dose was increased to 5ng / eye, it began to show a protective effect, and the protective effect was the best at 50ng / eye. However, given a high dose (200ng / eye), the protective effect of the drug on the blood-retinal barrier was weakened. But this attenuated effect, compared with the diabetic control group, was still significantly protective. Therefore, according to the r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method to prevent and treat retina injury of mammal, which comprises the following steps: giving effective dispense erythrocyte-stimulating factor (EPO) into vitreous chamber of injured eye; finishing the method. The EPO possesses the function of protecting retina vessel and neuron, which does not cause imperfect effect for other organ or tissue with local give medicine.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular, the invention relates to a method for preventing or treating retinal damage in mammals; the invention also relates to an intraocular injection preparation and a medicine box containing the intraocular injection preparation. Background technique [0002] Diabetic retinopathy (DR) is the leading cause of blindness in diabetic patients aged 20-70 years. The current understanding of diabetic retinopathy is: diabetic retinopathy is not only microvascular disease, it also involves the lesions of various types of cells in the retina (Gardner TW et al., Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47: S253-S262 , 2002; Erich Lieth et al (The PennState Retina Research Group): Retinal neurodegeneration: early pathology indiabetes. Clinical and Experimental Ophthalmology. 28: 3-8, 2000). The early clinical manifestations of diabetic retinopathy are the destruction of the blood-re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/22A61K38/18A61K9/08A61P27/02A61P3/10A61J1/00
CPCA61K38/1816A61K9/0048A61P27/02A61P3/10A61P9/14
Inventor 徐国彤李维业
Owner SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap